据证券之星公开数据整理，近期健帆生物（300529）发布2025年中报。根据财报显示，健帆生物净利润 同比下降29.46%。截至本报告期末，公司营业总收入11.34亿元，同比下降24.15%，归母净利润3.9亿 元，同比下降29.46%。按单季度数据看，第二季度营业总收入5.87亿元，同比下降21.92%，第二季度归 母净利润2.01亿元，同比下降24.95%。 本次财报公布的各项数据指标表现不尽如人意。其中，毛利率79.82%，同比减0.88%，净利率34.26%， 同比减6.96%，销售费用、管理费用、财务费用总计3.45亿元，三费占营收比30.44%，同比增5.02%，每 股净资产3.76元，同比增3.97%，每股经营性现金流0.67元，同比减27.35%，每股收益0.51元，同比减 26.09% 应收款项融资变动幅度为1225.7%,原因:本期末持有的银行承兑汇票增加。 递延所得税资产变动幅度为54.88%,原因:递延收益、股权激励费用产生的可抵扣暂时性差异。 应付职工薪酬变动幅度为-53.32%,原因:本期发放员工奖金。 其他流动负债变动幅度为157.63%,原因:本期收到客户预订货款增加。 递延收 ...

（文章来源：每日经济新闻） 国金证券8月22日发布研报称，给予健帆生物（300529.SZ，最新价：23.46元）买入评级。评级理由主 要包括：1）加强渠道管理，业绩增速短期承压；2）新系列产品拓展迅速，有望带动长期盈利能力提 升。风险提示：医保控费政策风险；在研项目推进不达预期风险；产品推广不达预期风险；院内需求及 产品使用频率不及预期风险。 ...

编制单位：健帆生物科技集团股份有限公司 单位：万元 本表已于 2025 年 8 月 21 日获第五届董事会第三十一次会议批准。 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的关 联关系 | 上市公司核 算的会计科 目 | 2025 年初占 用资金余额 | 2025 | 年半年度占用 累计发生金额（不含 利息） | 年半年 2025 度占用资金 的利息(如 有) | 2025 年半年度偿 还累计发生金额 | 2025 年 6 月 30 日 占用资金余额 | 占用形成原因 | | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | - | | | | | | | | | | | | | | - | | | | 小计 | | - - | | - | - | - | - | - | | - | - | | | 前控股股东、实际控制人及其附属 ...

证券代码：300529 证券简称：健帆生物 公告编号：2025-067 2025 年 8 月 21 日，健帆生物科技集团股份有限公司（以下简称"公司"） 召开第五届董事会第三十一次会议和第五届监事会第二十二次会议，审议通过了 《2025 年半年度报告》及《2025 年半年度报告摘要》。 为使投资者全面了解公司 2025 年半年度的经营成果及财务状况，公司《2025 年半年度报告》及《2025 年半年度报告摘要》将于 2025 年 8 月 22 日刊登在中 国证监会指定创业板信息披露网站巨潮资讯网（http://www.cninfo.com.cn），敬请 投资者注意查阅。 特此公告。 健帆生物科技集团股份有限公司董事会 2025 年 8 月 21 日 1 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 2025 年半年度报告披露的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 ...

证券代码：300529 证券简称：健帆生物 公告编号：2025-066 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 经与会监事认真讨论，审议并表决通过了以下议案： 1、审议通过了《2025 年半年度报告》及《2025 年半年度报告摘要》 经审核，监事会认为：董事会编制的公司《2025 年半年度报告》及《2025 年半年度报告摘要》的程序符合法律、行政法规和中国证监会的规定，报告内容 真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述 或者重大遗漏。 具体内容详见公司同日在中国证监会指定创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）发布的《2025 年半年度报告》及《2025 年半年度报 告摘要》。 表决情况：赞成 3 票，反对 0 票，弃权 0 票，0 票回避。本议案表决通过。 2、审议通过了《关于公司 2025 年半年度非经营性资金占用及其他关联资 金往来情况的议案》 第五届监事会第二十二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 ...

证券代码：300529 证券简称：健帆生物 公告编号：2025-065 健帆生物科技集团股份有限公司（以下简称"公司"）第五届董事会第三十 一次会议于 2025 年 8 月 21 日在公司会议室以现场会议及通讯表决的方式召开， 本次会议应出席董事 9 人，实际出席董事 9 人，符合《公司法》和《公司章程》 的有关规定。本次会议通知提前以电子邮件及电话通知等方式向全体董事送达。 公司董事长董凡先生召集和主持了本次会议，公司监事和部分高级管理人员列席 了会议。本次董事会的召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 第五届董事会第三十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 经与会董事认真讨论，审议并表决通过了以下议案： 1、审议通过了《2025 年半年度报告》及《2025 年半年度报告摘要》 经审核，董事会认为：公司编制的《2025 年半年度报告》及《2025 年半年 度报告摘要》的程序符合法律、行政法规和中国证监会的 ...

[Important Notice, Table of Contents and Definitions](index=2&type=section&id=Item%20I.%20Important%20Notice%2C%20Table%20of%20Contents%20and%20Definitions) [Company Profile and Key Financial Indicators](index=7&type=section&id=Item%20II.%20Company%20Profile%20and%20Key%20Financial%20Indicators) [Company Profile](index=7&type=section&id=I.%20Company%20Profile) Jafron Biomedical Co., Ltd. (stock code: 300529) is a company listed on the Shenzhen Stock Exchange, with Dong Fan as its legal representative Company Information | Item | Information | | :--- | :--- | | **Stock Abbreviation** | Jafron Biomedical | | **Stock Code** | 300529 | | **Listing Exchange** | Shenzhen Stock Exchange | | **Company Name** | Jafron Biomedical Co., Ltd. | | **Legal Representative** | Dong Fan | [Key Accounting Data and Financial Indicators](index=8&type=section&id=IV.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) During the reporting period, the company's operating revenue and net profit both significantly declined, with operating revenue at **1.134 billion Yuan**, down **24.15%** year-on-year, and net profit attributable to shareholders at **389.72 million Yuan**, down **29.46%** year-on-year, while net cash flow from operating activities was **538.28 million Yuan**, a **28.16%** decrease Key Financial Indicators | Key Financial Indicators | Current Reporting Period | Prior Year Same Period | Year-on-Year Change | | :--- | :--- | :--- | :--- | | **Operating Revenue (Billion Yuan)** | 1.134 | 1.496 | -24.15% | | **Net Profit Attributable to Shareholders (Million Yuan)** | 389.72 | 552.51 | -29.46% | | **Net Profit Attributable to Shareholders Excluding Non-Recurring Gains and Losses (Million Yuan)** | 372.95 | 525.88 | -29.08% | | **Net Cash Flow from Operating Activities (Million Yuan)** | 538.28 | 749.27 | -28.16% | | **Basic Earnings Per Share (Yuan/share)** | 0.51 | 0.69 | -26.09% | | **Weighted Average Return on Net Assets** | 11.35% | 16.91% | -5.56% | | **Total Assets (Billion Yuan)** | 5.267 | 5.383 | -2.16% (Period-end vs. Prior Year-end) | | **Net Assets Attributable to Shareholders (Billion Yuan)** | 3.123 | 3.334 | -6.33% (Period-end vs. Prior Year-end) | [Non-Recurring Gains and Losses and Amounts](index=8&type=section&id=VI.%20Non-Recurring%20Gains%20and%20Losses%20and%20Amounts) During the reporting period, the company's total non-recurring gains and losses amounted to **16.77 million Yuan**, primarily from fair value changes and investment income on financial assets, government subsidies, and non-operating expenses Non-Recurring Gains and Losses | Item | Amount (Million Yuan) | | :--- | :--- | | Gains/Losses from Disposal of Non-Current Assets | -1.46 | | Government Subsidies Recognized in Current Profit/Loss | 10.28 | | Gains/Losses from Fair Value Changes and Disposal of Financial Assets and Liabilities | 29.93 | | Other Non-Operating Income and Expenses | -19.27 | | **Total** | **16.77** | [Management Discussion and Analysis](index=10&type=section&id=Item%20III.%20Management%20Discussion%20and%20Analysis) [Company's Main Businesses, Operating Models, and Industry Development](index=10&type=section&id=I.%20Company's%20Main%20Businesses%20During%20the%20Reporting%20Period) The company focuses on R&D, production, and sales of blood purification products, with core products including hemoperfusion cartridges, maintaining strong gross and net profit margins despite revenue decline due to a high base, while expanding new products and international markets - The company's main business involves the R&D, production, and sales of biomaterials and high-tech medical devices, with core products including disposable hemoperfusion cartridges, plasma bilirubin adsorbers, hemodialysis powder/liquid, and blood purification equipment[29](index=29&type=chunk) - Product applications cover four major areas: nephrology, hepatology, critical care, and immunology, offering diverse treatment solutions for various diseases[29](index=29&type=chunk) - In the first half of 2025, the company achieved operating revenue of **1.134 billion Yuan**, a **24.15%** year-on-year decrease, and net profit of **389 million Yuan**, a **29.46%** year-on-year decrease, primarily due to a high base from significant sales growth in the prior year due to product price reductions[56](index=56&type=chunk) - The company maintains strong profitability, with a gross profit margin of **79.82%** and a net profit margin of **34.26%** during the reporting period, and net cash flow from operating activities of **538.28 million Yuan**, exceeding current net profit[56](index=56&type=chunk) [Main Businesses and Products](index=10&type=section&id=(I)%20Company's%20Main%20Businesses%20and%20Products) - The company's main business involves the R&D, production, and sales of biomaterials and high-tech medical devices, with core products including disposable hemoperfusion cartridges, plasma bilirubin adsorbers, hemodialysis powder/liquid, and blood purification equipment[29](index=29&type=chunk) - Product applications cover four major areas: nephrology, hepatology, critical care, and immunology, offering diverse treatment solutions for various diseases[30](index=30&type=chunk)[31](index=31&type=chunk) Main Products and Applications by Field | Field | Main Products and Uses | | :--- | :--- | | **Nephrology** | HA, KHA, PHA series hemoperfusion cartridges, used for uremia patients at different stages and with complications | | **Hepatology** | HA330-II hemoperfusion cartridges, BS series plasma bilirubin adsorbers, used for severe liver disease treatment | | **Critical Care** | HA330/HA380 hemoperfusion cartridges, CA series cytokine adsorption columns, used for poisoning, sepsis, etc. | | **Immunology** | HA280 hemoperfusion cartridges, DNA230 immune adsorption columns, used for rheumatic immune diseases and systemic lupus erythematosus | - As of the end of the reporting period, the company holds **29** medical device registration certificates (**25** of which are Class III), and newly obtained **1** product registration certificate and **2** CE certifications[35](index=35&type=chunk) [Main Operating Models](index=15&type=section&id=(II)%20Main%20Operating%20Models) - The company adopts a combination of independent R&D and collaborative R&D, focusing on building continuous independent R&D capabilities[40](index=40&type=chunk) - Core raw material HA resin is procured through a directed purchasing model, where the company provides key formulations and processes, and suppliers produce exclusively for the company under guidance[41](index=41&type=chunk) - The production model involves batch continuous production of standardized products, maintaining approximately two months of safety stock[42](index=42&type=chunk) - The sales model is primarily distributor buy-out, but the company builds its own promotion team for market development, academic promotion, and technical services to control the market[43](index=43&type=chunk) [Industry Development During the Reporting Period](index=16&type=section&id=(III)%20Industry%20Development%20During%20the%20Reporting%20Period) - In 2023, the global medical device market reached **582.6 billion USD**, a **9.35%** year-on-year increase, while the Chinese market reached **1.03 trillion Yuan**, a **7.79%** year-on-year increase[45](index=45&type=chunk) - The National Healthcare Security Administration's June 2025 guidelines added "Hemodialysis Perfusion Fee" and "Plasma Adsorption Fee" items, signifying national recognition of hemoperfusion technology and potential policy-driven growth[47](index=47&type=chunk) - As of the end of 2024, China had approximately **1.027 million** hemodialysis patients, a **12%** year-on-year increase, but the dialysis treatment rate remains significantly lower than in Europe and the US, indicating huge market growth potential[47](index=47&type=chunk) - The company's pioneering DPMAS technology (artificial liver treatment model) has been incorporated into six guidelines, four consensuses, and three norms, providing crucial evidence-based support for clinical application[49](index=49&type=chunk)[50](index=50&type=chunk) [Company's Industry Position](index=18&type=section&id=(IV)%20Company's%20Industry%20Position) - The company holds a dominant position in China's hemoperfusion cartridge industry and was recognized as a "Sixth Batch Manufacturing Single Champion Demonstration Enterprise" by the Ministry of Industry and Information Technology in November 2021[55](index=55&type=chunk) [Key Performance Drivers](index=18&type=section&id=(V)%20Key%20Performance%20Drivers) Performance Drivers by Business Segment | Business Segment | Revenue During Reporting Period (Million Yuan) | Revenue Share | Key Progress | | :--- | :--- | :--- | :--- | | **Nephrology** | 784.97 | 69.20% | KHA series product revenue increased by **27.34%** year-on-year, and PHA series by **374.22%** year-on-year | | **Hepatology** | 131.53 | 11.59% | DPMAS technology newly included in "Guidelines for Diagnosis and Treatment of Chronic-on-Acute Liver Failure" | | **Critical Care** | 142.31 | 12.54% | CA series cytokine adsorption column revenue increased by **36.15%** year-on-year | | **Blood Purification Equipment** | 19.34 | 1.71% | Future F20 equipment obtained EU MDR CE certification | | **International Business** | 34.44 | 3.04% | Products are applied in over **2,000** hospitals across **98** countries | - R&D investment during the reporting period was **97 million Yuan**, accounting for **8.59%** of revenue, with **15** new authorized patents obtained (**3** for invention)[74](index=74&type=chunk) - The company completed its 2024 profit distribution, paying **620 million Yuan** in cash dividends, with a dividend payout ratio exceeding **75%**, and cumulative dividends since listing totaling **4.07 billion Yuan**, **2.9 times** the IPO and refinancing amounts[76](index=76&type=chunk) [Analysis of Core Competitiveness](index=22&type=section&id=II.%20Analysis%20of%20Core%20Competitiveness) The company's core competitiveness stems from its technological leadership, robust marketing system, stringent quality control, and strong human resources, ensuring sustained development - The company possesses national enterprise technology centers and academician workstations, was awarded the National Science and Technology Progress Award (Second Prize), and holds complete independent intellectual property rights from raw materials to products[78](index=78&type=chunk) - Core technological advantages include carrier preparation, encapsulation, ligand, and medical-grade purification technologies, ensuring product adsorption efficacy and biocompatibility[80](index=80&type=chunk)[81](index=81&type=chunk) - A professional academic promotion team of over **1,000** people cultivates market demand through a multi-level academic promotion system[84](index=84&type=chunk) - The company was among the first batch of enterprises nationwide to pass medical device GMP inspection, with products certified under MDR regulations, CE, and ISO international quality management systems, ensuring product quality[85](index=85&type=chunk) [Analysis of Main Business](index=24&type=section&id=III.%20Analysis%20of%20Main%20Business) During the reporting period, the company's key financial metrics declined year-on-year, with operating revenue down **24.15%**, while financial expenses significantly increased by **151.30%** due to reduced deposit interest income, and the core product's gross margin remained stable at **84.55%** Key Financial Indicators and Changes | Financial Indicator | Current Reporting Period (Million Yuan) | Year-on-Year Change | Main Reasons for Change | | :--- | :--- | :--- | :--- | | **Operating Revenue** | 1,134.42 | -24.15% | - | | **Selling Expenses** | 249.61 | -26.75% | - | | **Administrative Expenses** | 75.36 | -10.99% | - | | **Financial Expenses** | 20.35 | 151.30% | Decrease in deposit ratio, reduction in deposit interest income | | **Income Tax Expense** | 73.24 | -33.12% | Reduced profit leading to lower income tax | | **R&D Investment** | 97.46 | -13.59% | - | Main Product Performance | Main Product | Operating Revenue (Million Yuan) | Operating Cost (Million Yuan) | Gross Profit Margin | Year-on-Year Revenue Change | | :--- | :--- | :--- | :--- | :--- | | **Disposable Hemoperfusion Cartridge** | 965.22 | 149.12 | 84.55% | -25.25% | [Analysis of Non-Main Business](index=24&type=section&id=IV.%20Analysis%20of%20Non-Main%20Business) Non-main business activities impacted total profit, with positive contributions from fair value changes and investment income on wealth management products, offset by negative impacts from non-operating expenses (donations) and asset impairment (inventory write-downs), none of which are sustainable Non-Main Business Impact on Profit | Item | Amount (Million Yuan) | Share of Total Profit | Reason for Formation | | :--- | :--- | :--- | :--- | | **Investment Income** | 8.33 | 1.80% | Mainly from gains on disposal of wealth management products | | **Gains/Losses from Fair Value Changes** | 21.55 | 4.67% | Mainly from fair value changes of held wealth management products | | **Asset Impairment** | -6.25 | -1.35% | Mainly from provision for inventory depreciation losses | | **Non-Operating Expenses** | 19.45 | 4.21% | Mainly from donation expenses | [Analysis of Assets and Liabilities](index=25&type=section&id=V.%20Analysis%20of%20Assets%20and%20Liabilities) At the end of the reporting period, total assets were **5.267 billion Yuan**, slightly down from the beginning of the period, with a significant shift from cash to transactional financial assets due to wealth management product purchases, while accounts receivable management improved - Cash and bank balances at period-end were **748 million Yuan**, a decrease from the beginning of the period, with its proportion of total assets falling from **32.04%** to **14.19%**, primarily due to wealth management product purchases and dividend distributions[96](index=96&type=chunk) - Transactional financial assets at period-end were **1.441 billion Yuan**, a significant increase from the beginning of the period, with its proportion of total assets rising from **11.02%** to **27.36%**, mainly due to wealth management product purchases[96](index=96&type=chunk) - Accounts receivable at period-end were **25.03 million Yuan**, a substantial decrease from **53.46 million Yuan** at the beginning of the period, indicating the company's continuous efforts in accounts receivable management[96](index=96&type=chunk) [Analysis of Investment Status](index=27&type=section&id=VI.%20Analysis%20of%20Investment%20Status) During the reporting period, the company's investment activities focused on significant non-equity investments and entrusted wealth management, with **30.24 million Yuan** invested in the "Biomaterials Project" and **14.12 million Yuan** in the "Medical Device Industry (Blood Purification) Project (Phase II)," alongside **2.611 billion Yuan** in entrusted wealth management with no overdue amounts Major Self-Built Investment Projects | Project Name | Amount Invested in Current Reporting Period (Million Yuan) | Cumulative Investment Amount as of Period-End (Million Yuan) | Project Progress | | :--- | :--- | :--- | :--- | | **Biomaterials Project** | 30.24 | 238.09 | 88.00% | | **Medical Device Industry (Blood Purification) Project (Phase II)** | 14.12 | 14.48 | 5.00% | Entrusted Wealth Management | Specific Type | Amount of Entrusted Wealth Management (Billion Yuan) | Unmatured Balance (Billion Yuan) | Overdue Unrecovered Amount (Million Yuan) | | :--- | :--- | :--- | :--- | | **Bank Wealth Management Products (Own Funds)** | 2.59 | 1.41 | 0 | | **Bank Wealth Management Products (Other)** | 21.51 | 9.30 | 0 | | **Total** | **2.611** | **1.42** | **0** | [Risks and Countermeasures](index=35&type=section&id=X.%20Risks%20and%20Countermeasures) The company faces market, competition, technology, quality, policy, and centralized procurement risks, which it addresses through enhanced academic promotion, technological innovation, automation, quality control, market expansion, and product diversification - The company's revenue is highly dependent on disposable hemoperfusion cartridges, facing risks of market growth falling short of expectations or significant adverse changes[126](index=126&type=chunk) - Increased industry competition due to new entrants may impact the company's product profitability[127](index=127&type=chunk) - The medical device industry experiences rapid technological updates, and the company risks being impacted by substitute products if it fails to innovate continuously[128](index=128&type=chunk) - While the company's core hemoperfusion cartridge products are not yet included in national or provincial centralized procurement, their future inclusion could lead to product price reductions and decreased gross profit margins[132](index=132&type=chunk) [Corporate Governance, Environment and Society](index=38&type=section&id=Item%20IV.%20Corporate%20Governance%2C%20Environment%20and%20Society) [Implementation of Equity Incentive Plans, Employee Stock Ownership Plans or Other Employee Incentive Measures](index=38&type=section&id=III.%20Implementation%20of%20Equity%20Incentive%20Plans%2C%20Employee%20Stock%20Ownership%20Plans%20or%20Other%20Employee%20Incentive%20Measures) During the reporting period, the company canceled some stock options from its 2022 equity incentive plan due to unmet performance targets and employee departures, while its "Striver No. 1" and "Striver No. 2" employee stock ownership plans reached their lock-up periods, with **18.575 million Yuan** in share-based payment expenses recognized - **1,028,000** stock options from the 2022 stock option incentive plan were canceled due to unmet performance targets and the departure of some incentive recipients[141](index=141&type=chunk) - The lock-up periods for the "Striver No. 1" and "Striver No. 2" employee stock ownership plans expired on September 7, 2024, and September 17, 2024, respectively[142](index=142&type=chunk)[143](index=143&type=chunk) - During the reporting period, the company recognized **18.575 million Yuan** in share-based payment expenses related to the Striver No. 1 and Striver No. 2 employee stock ownership plans[146](index=146&type=chunk) [Social Responsibility](index=41&type=section&id=V.%20Social%20Responsibility) In the first half of 2025, the company actively fulfilled its social responsibilities by donating **19.17 million Yuan** in cash and materials for charity, rural revitalization, and social healthcare, earning multiple social responsibility awards - During the reporting period, the company donated **19.17 million Yuan** in cash and materials for charitable causes, rural revitalization, and other projects[148](index=148&type=chunk) - The company received honors such as "Zhuhai City 2024 Red Cross Outstanding Contribution Unit" and "Zhuhai Federation of Industry and Commerce Outstanding Contribution Award for Philanthropy"[148](index=148&type=chunk) [Significant Matters](index=42&type=section&id=Item%20V.%20Significant%20Matters) [Significant Contracts and Their Performance](index=44&type=section&id=XII.%20Significant%20Contracts%20and%20Their%20Performance) During the reporting period, the company provided a significant guarantee of **230 million Yuan** to its wholly-owned subsidiary, Zhuhai Jian Shu New Material Technology Co., Ltd., with an actual outstanding guarantee balance of **135 million Yuan** at period-end, representing **4.32%** of the company's net assets Significant Guarantees | Guaranteed Party | Guaranteed Amount (Million Yuan) | Actual Outstanding Guarantee Balance at Period-End (Million Yuan) | Proportion of Company's Net Assets | | :--- | :--- | :--- | :--- | | **Zhuhai Jian Shu New Material Technology Co., Ltd.** | 230 | 134.91 | 4.32% | [Share Changes and Shareholder Information](index=46&type=section&id=Item%20VI.%20Share%20Changes%20and%20Shareholder%20Information) [Share Changes](index=46&type=section&id=I.%20Share%20Changes) During the reporting period, the company's total share capital remained unchanged at **798,605,275** shares, but restricted shares increased by **881,219** due to a vice general manager's resignation, leading to a corresponding decrease in unrestricted shares - Total share capital remained unchanged at **798,605,275** shares during the reporting period[177](index=177&type=chunk) - Due to the resignation of Vice General Manager Mr. Li Dezhi, his shares were locked, increasing restricted shares from **286,138,075** to **287,019,294** shares[177](index=177&type=chunk)[178](index=178&type=chunk)[180](index=180&type=chunk) [Number of Shareholders and Shareholding Information](index=47&type=section&id=III.%20Number%20of%20Shareholders%20and%20Shareholding%20Information) As of the end of the reporting period, the company had **51,650** common shareholders, with controlling shareholder and actual controller Mr. Dong Fan holding **44.47%** of shares, and the top ten shareholders primarily comprising the controlling shareholder, related parties, public funds, and employee stock ownership plans - The total number of common shareholders at the end of the reporting period was **51,650**[183](index=183&type=chunk) Top Ten Shareholders | Shareholder Name | Shareholder Type | Shareholding Percentage | Number of Shares Held at Period-End (Shares) | | :--- | :--- | :--- | :--- | | **Dong Fan** | Domestic Natural Person | 44.47% | 355,131,867 | | **Tang Xianmin** | Domestic Natural Person | 2.67% | 21,336,425 | | **Huabao CSI Medical ETF** | Other | 2.02% | 16,159,051 | | **E Fund ChiNext ETF** | Other | 1.35% | 10,741,712 | | **Guo Xuerui** | Domestic Natural Person | 1.01% | 8,040,792 | - Among the top ten shareholders, Jiang Huanxin is the brother-in-law of Dong Fan's wife, and Huang He is Dong Fan's brother[183](index=183&type=chunk) [Bond-Related Information](index=51&type=section&id=Item%20VII.%20Bond-Related%20Information) [Convertible Corporate Bonds](index=51&type=section&id=IV.%20Convertible%20Corporate%20Bonds) The company's "Jafron Convertible Bond" (code 123117) with a total issuance of **1 billion Yuan** remains outstanding, with minimal conversion to shares as of period-end; the conversion price was adjusted from **39.43 Yuan/share** to **38.65 Yuan/share** due to the 2024 equity distribution, and the company's and bond's credit ratings remain AA with a stable outlook - The company issued **1 billion Yuan** in convertible corporate bonds, "Jafron Convertible Bond," in June 2021, with a maturity date of June 22, 2027[193](index=193&type=chunk) - As of the end of the reporting period, the cumulative converted amount was **0.1581 million Yuan**, a very low proportion of the total issuance, with **999.8 million Yuan** (or **99.98%** of the total issuance) yet to be converted[196](index=196&type=chunk) - During the reporting period, due to the implementation of the 2024 equity distribution, the conversion price was adjusted from **39.43 Yuan/share** to **38.65 Yuan/share** on May 26, 2025[199](index=199&type=chunk)[602](index=602&type=chunk) - In June 2025, China Chengxin International Credit Rating Co., Ltd. maintained the company's and the bond's credit ratings at **AA** with a stable outlook[200](index=200&type=chunk) [Financial Report](index=55&type=section&id=Item%20VIII.%20Financial%20Report) [Financial Statements](index=55&type=section&id=II.%20Financial%20Statements) This section presents the company's unaudited consolidated and parent company financial statements for the first half of 2025, including the balance sheet, income statement, cash flow statement, and statement of changes in owners' equity, reflecting the financial position, operating results, and cash flows Consolidated Balance Sheet (Period-End) | Item | Period-End Balance (Billion Yuan) | Period-Beginning Balance (Billion Yuan) | | :--- | :--- | :--- | | **Total Assets** | 5.267 | 5.383 | | **Total Liabilities** | 2.145 | 2.049 | | **Total Owners' Equity** | 3.122 | 3.335 | Consolidated Income Statement (Current Period) | Item | H1 2025 (Billion Yuan) | H1 2024 (Billion Yuan) | | :--- | :--- | :--- | | **Total Operating Revenue** | 1.134 | 1.496 | | **Operating Profit** | 481.17 | 676.98 | | **Net Profit** | 388.67 | 550.76 | | **Net Profit Attributable to Parent Company Shareholders** | 389.72 | 552.51 | Consolidated Cash Flow Statement (Current Period) | Item | H1 2025 (Million Yuan) | H1 2024 (Million Yuan) | | :--- | :--- | :--- | | **Net Cash Flow from Operating Activities** | 538.28 | 749.27 | | **Net Cash Flow from Investing Activities** | -889.99 | -1,115.35 | | **Net Cash Flow from Financing Activities** | -627.47 | -646.33 | | **Net Increase in Cash and Cash Equivalents** | -979.09 | -1,012.32 | [Notes to Consolidated Financial Statements](index=105&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statements) This section details key consolidated financial statement items, including a significant decrease in period-end cash due to wealth management product purchases, a surge in transactional financial assets, a notable decline in accounts receivable, a slight decrease in inventory with increased impairment provisions, and steady progress in construction-in-progress projects - Period-end cash and bank balances were **748 million Yuan**, of which **7.719 million Yuan** were restricted funds (e.g., guarantees)[420](index=420&type=chunk) - Period-end transactional financial assets totaled **1.441 billion Yuan**, entirely comprising wealth management products[421](index=421&type=chunk) - Period-end accounts receivable book balance was **29.62 million Yuan**, a significant decrease from **58.56 million Yuan** at the beginning of the period, with a bad debt provision ratio of **15.50%**[430](index=430&type=chunk)[432](index=432&type=chunk) - Period-end inventory book value was **328 million Yuan**, with an inventory depreciation provision of **11.85 million Yuan**, an increase from **5.65 million Yuan** at the beginning of the period[489](index=489&type=chunk)[493](index=493&type=chunk) - Period-end construction-in-progress book value was **304 million Yuan**, primarily for the Biomaterials Project (**231 million Yuan**) and the Hollow Fiber Membrane Spinning Production Line Project (**56.03 million Yuan**)[544](index=544&type=chunk)

Group 1 - The core viewpoint of the news is that Jianfan Biological Technology Group Co., Ltd. has experienced a decline in both revenue and net profit in its latest quarterly report, indicating potential challenges in its financial performance [1][3] - As of August 19, 2025, Jianfan Biological's stock closed at 23.57 yuan, down 0.67%, with a trading volume of 84,200 hands and a transaction amount of 200 million yuan [1] - The company's total revenue for the first quarter of 2025 was 548 million yuan, a year-on-year decrease of 26.40%, while the net profit attributable to shareholders was 189 million yuan, down 33.71% year-on-year [1] Group 2 - Jianfan Biological has made investments in 17 companies and participated in 545 bidding projects, showcasing its active engagement in the market [2] - The company holds 95 trademark registrations and 380 patent applications, indicating a strong focus on intellectual property [2] - Additionally, Jianfan Biological possesses 305 administrative licenses, reflecting its compliance and operational capabilities [2]

证券代码：300529 证券简称：健帆生物 公告编号：2025-062 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于健帆转债回售结果的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 一、本次可转换公司债券回售的公告情况 健帆生物科技集团股份有限公司（以下简称"公司"）根据《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 15 号—— 可转换公司债券》等法律法规的有关规定以及《健帆生物科技集团股份有限公司 创业板向不特定对象发行可转换公司债券募集说明书》（以下简称"《募集说明 书》"）的相关约定，分别于 2025 年 8 月 1 日、2025 年 8 月 4 日、2025 年 8 月 5 日、2025 年 8 月 6 日、2025 年 8 月 7 日、2025 年 8 月 8 日、2025 年 8 月 11 日、2025 年 8 月 12 日、2025 年 8 月 13 日在中国证监会指定的创业板信息披 露网站巨潮资讯网（www.cninfo.com.cn）上披露了《关于健帆转债回售 ...

债券代码：123117 债券简称：健帆转债 证券代码：300529 证券简称：健帆生物 公告编号：2025-061 健帆生物科技集团股份有限公司 关于健帆转债恢复转股的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、债券代码：123117 债券简称：健帆转债 2、证券代码：300529 证券简称：健帆生物 3、转股期限：2021 年 12 月 29 日至 2027 年 6 月 22 日 4、暂停转股时间：2025 年 8 月 8 日至 2025 年 8 月 14 日 5、恢复转股时间：2025 年 8 月 15 日 经中国证券监督管理委员会"证监许可[2020]3617号"文同意注册，健帆生 物科技集团股份有限公司（以下简称"公司"）于2021年6月23日向不特定对象 发行了1,000.00万张可转换公司债券，每张面值100元，发行总额人民币100,000.00 万元，期限为自发行之日起6年，自2021年12月29日至2027年6月22日可转换为公 司股份，目前"健帆转债"处于转股期。 公司股票自 2025 年 6 月 23 日至 ...